• OFID 2018:5 (Suppl 1) • Poster Abstracts frequently require greater than 1 year of therapy. Although the toxicity profile of fluconazole has been evaluated in clinical trials, there is a paucity of data regarding the tolerability of this agent with long-term therapy.
Background.
Patients with coccidioidal meningitis require life-long antifungal therapy and cumulative toxicity from these agents may occur. Isavuconazole is the newest triazole antifungal and has demonstrated a lower toxicity profile than voriconazole and may represent a useful therapy in meningitis, although no data regarding efficacy in coccidioidal meningitis has yet been presented.
Methods. We conducted a retrospective analysis of all coccidioidal meningitis patients treated at our centers. Data abstracted included demographic and clinical information, results of laboratory and radiographic studies, serologic results, and outcomes. Responses to therapy were measured using a previously validated scoring system used in clinical trials of coccidioidal meningitis (MSG Coccidioidomycosis Scoring System).
Results. Nine patients met criteria for inclusion. Seven of nine were previously treated with voriconazole and transitioned to isavuconazole following: photodermatitis, five patients; transaminitis and photodermatitis one patient; failure of therapy, one patient. Two other patients failed fluconazole therapy and were transitioned to isavuconazole as salvage therapy. All patients transitioned to isavuconazole had a complete response to therapy five patients; or were deemed partial response (stable disease), four patients.
Conclusion. Isavuconazole therapy resulted in symptomatic and laboratory improvement in five of nine patients. The remaining patients exhibited clinical resolution of symptoms or continued with stable disease following adverse reactions to prior alternative triazole therapy. Isavuconazole may be a useful addition to the therapeutic choices currently available for coccidioidal meningitis.
Disclosures. All authors: No reported disclosures. Background. Differentiating between localized and disseminated cryptococcal disease is key to the management of this infection, since induction therapy with amphotericin B and flucytosine is warranted in the latter. We compared mortality in disseminated Cryptococcus with non-central nervous system (CNS) involvement, with those with CNS involvement and localized pulmonary disease.
Outcomes in Patients With
Methods. Demographics, predisposing factors, presentation, laboratory values, treatment and outcome data were collected retrospectively on patients hospitalized at an academic tertiary-care hospital for cryptococcal infection from 2002 to 2017. Outcomes were compared between three patient groups based on extra-pulmonary and CNS involvement. Survival analysis was performed using univariate and multivariate Cox Regression with censoring at 90 days.
Results. Of 312 patients identified, 63 (20%) had pulmonary, 154 (49.2%) CNS and 95 (30.4%) had disseminated non-CNS disease. At day 90, 38 (40%) from the disseminated non-CNC group had died, compared with 37 (24%) in the CNS disease and 13 (20.6%) in the pulmonary groups. After adjusting for age ≥55 years, organ transplant, end-stage liver disease (ESLD) and AIDS, 90-day mortality risk was higher in the disseminated non-CNS group compared with the pulmonary (HR 2.97 [95% CI 1.55, 5.7] ; P = 0.001) and the CNS disease group (1.84 [1.16, 2.93] ; P = 0.009) (Figure 1 ). Median [IQR] time to diagnosis was 10 [4, 19] days and not significantly different between groups (P = 0.752). Induction therapy for ≥2 weeks was more common in the CNS disease (64.3%) that in the pulmonary (33.3%) or disseminated non-CNS disease group (38.7%) (P = 0.01). Median duration of azole therapy in days was longer (315 [61, 750] ) in the CNS disease than in the disseminated non-CNS (184 [23.5, 403.5]) or the pulmonary group (214 [86, 415] ) (P = 0.04).
Conclusion. Patients with disseminated cryptococcal disease without CNS involvement have higher risk for mortality than those with CNS disease. However, management of patient's disseminated non-CNS cryptococcosis was similar to those with localized pulmonary infection. 
